
March 4 (Reuters) - Citius Oncology Inc CTOR.O:
CITIUS ONCOLOGY ANNOUNCES PRELIMINARY TOPLINE PHASE 1 DATA FROM STUDY OF LYMPHIR™ (E7777) DOSING PRIOR TO COMMERCIAL CAR‑T THERAPY IN HIGH‑RISK DIFFUSE LARGE B‑CELL LYMPHOMA
CITIUS ONCOLOGY INC - LYMPHIR WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED IN PHASE 1 STUDY
CITIUS ONCOLOGY INC - PHASE 1 STUDY SHOWS 86% OVERALL RESPONSE RATE, 57% COMPLETE RESPONSE, 29% PARTIAL RESPONSE